Satellos Bioscience Inc · TSX:MSCL

Satellos Bioscience — Investor Presentation (June 2025)

22 slides from Satellos Bioscience's investor presentation, Jun 5, 2025

1. Slide 1: Regenerating Muscle from Within

   © 2025 Satellos Bioscience R E G E N E R AT I N G M U S C L E F R O M W I T H I N T M

2. Slide 2: Legal Disclaimers

   © 2025 Satellos Bioscience Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any The information contained herein is subject to change without statements that express or involve discussions with respect to predictions, expect

3. Slide 3: Regenerating Muscle and Restoring Function with SAT-3247

   © 2025 Satellos Bioscience Regenerating Muscle and Restoring Function with SAT-3247  Disruptive, differentiated approach  Disease modifying potential in DMD  Safe, well-tolerated, oral pill taken daily  Intended to increase function vs delaying loss  Applications in multiple degenerative condit

4. Slide 4: Grounded in science. Inspired by need.

   © 2025 Satellos Bioscience Grounded in science. Inspired by need. Our mission is to improve the treatment of Duchenne muscular dystrophy and other devastating muscle diseases by restoring the body’s ability to regenerate muscle. CHARLIE, age 7, living with Duchenne 4

5. Slide 5: Rewriting the Duchenne Story

   © 2025 Satellos Bioscience Rewriting the Duchenne Story Infants 2 to 4 years 5 to 9 years 10 to 12 years 13 to 19 years 20+ Often no visible Signs of early Damage begins to ≥70% of boys lose the Ventilator support needed; Increasing heart and symptoms muscle weakness outpace regeneration ability to

6. Slide 6: In DMD, Regeneration Fails as Muscle Stem Cells Don’t Function as Intended

   © 2025 Satellos Bioscience In DMD, Regeneration Fails as Muscle Stem Cells Don’t Function as Intended DMD Patients Have an Excess of SATELLOS DISCOVERY Stem Cells vs Progenitor Cells Muscle Stem Cells Don’t Divide Properly due to Missing a ‘SIGNAL’ Normally Provided by Dystrophin Not Enough Progenit

7. Slide 7: Satellos is Developing SAT-3247 to Address This Problem

   © 2025 Satellos Bioscience Satellos is Developing SAT-3247 to Address This Problem RESTORING MUSCLE REGENERATION with SAT-3247 SAT-3247 inhibits AAK1 to replace the missing dystrophin ‘SIGNAL’ and reset proper muscle stem cell divisions SAT-3247 has been designed as an oral pill One Progenitor Cell

8. Slide 8: SAT-3247 is Totally Different: Not Just Stabilizing — Regenerating

   © 2025 Satellos Bioscience SAT-3247 is Totally Different: Not Just Stabilizing — Regenerating Genetic approaches SAT-3247 Approach  Administered by infusion or injection  Oral, once-daily pill  Gene therapy (DNA) or exon skipping (RNA)  Designed to be safe and tolerable  Aims to stabilize muscl

9. Slide 9: Preclinical Proof of Concept with SAT-3247

   © 2025 Satellos Bioscience Preclinical Proof of Concept with SAT-3247

10. Slide 10: SAT-3247 Restores Muscle Strength to Normative Levels in Canine Model of DMD

    © 2025 Satellos Bioscience SAT-3247 Restores Muscle Strength to Normative Levels in Canine Model of DMD SAT-3247 treated vs. natural history Flexion Tetanic Torque Satellos Preclinical Study  4-month study  2 dogs: ~9 months of age to ~13 months  Retriever cross with natural DMD mutation  Oral d

11. Slide 11: SAT-3247 Treatment Shows Evidence of Muscle Repair and Regeneration

    © 2025 Satellos Bioscience SAT-3247 Treatment Shows Evidence of Muscle Repair and Regeneration 500um 500um SAT-3247 Study SAT-3247 Study Healthy Age-Matched DMD Animal / Pre-Treatment DMD Animal / Post-Treatment Non-DMD Comparator Bicep Femoris Bicep Femoris Bicep Femoris 11

12. Slide 12: Regenerative Index and Inflammatory Markers Offer Potential for Use in Clinical Development

    © 2025 Satellos Bioscience Regenerative Index and Inflammatory Markers Offer Potential for Use in Clinical Development Regenerative Index (RI) Inflammatory Markers (from tissue biopsy) (from serum) Cytokine % Change Decrease GM-CSF -73 IL-7 -70 IL-18 -62 IL-2 -56 eMHC/IgG IL-6 -53 IL-15 -38 KC-Like

13. Slide 13: Advancing SAT-3247 into Clinical Development

    © 2025 Satellos Bioscience Advancing SAT-3247 into Clinical Development

14. Slide 14: SAT-3247 Phase 1 First-in-Human Clinical Trial

    © 2025 Satellos Bioscience SAT-3247 Phase 1 First-in-Human Clinical Trial Ph 1a: Healthy Volunteers (n=72) Ph 1b: DMD Adults SAD* Study MAD* Study Food Effect Study 28-day, Open-Label Study  10 - 400 mg  60 - 240 mg  150 mg  60 mg daily dose  5 cohorts of 8  4 cohorts of 8  1 cohort of 8  1

15. Slide 15: SAT-3247 Appears Safe and Tolerable in Phase 1a

    © 2025 Satellos Bioscience SAT-3247 Appears Safe and Tolerable in Phase 1a Single Ascending Dose1 Multiple Ascending Dose1 No clinically significant findings observed in No clinically significant findings observed in 10, 50, 150, 300 and 400 mg doses. 60, 120, 180 and 240 mg doses: Labs Labs (mild A

16. Slide 16: SAT-3247 Achieved Desired Profile Determined by Satellos

    © 2025 Satellos Bioscience SAT-3247 Achieved Desired Profile Determined by Satellos SAT-3247 Exposure (PK) Achieved SAT-3247 Target Dose Achieved 150mg Target Range 50mg Exposure (PK) Targets: Dose Targets:  Dose proportional exposure levels  Exposure ≥IC50 for 6-8 hours  Drug clearance within 24

17. Slide 17: SAT-3247 Treatment Displayed Encouraging Results and Possible Early Functional Signal in Phase 1b

    © 2025 Satellos Bioscience SAT-3247 Treatment Displayed Encouraging Results and Possible Early Functional Signal in Phase 1b Study Overview Exploratory Measures: Data Highlights  Safety and PK plus exploratory  Grip strength (days 1 and 28): measures assessed  Avg. ~2kg (108%)  3 patients showed

18. Slide 18: Comparison of Force Increase in Grip Strength

    © 2025 Satellos Bioscience Comparison of Force Increase in Grip Strength Satellos vs Competitor Satellos Data Competitor Data (exon skipping) Non-dominant Hand Dominant Hand SAT-3247  11 patients: ~ 8 years old  48 weeks of treatment  5 patients: 20-27 years old  + ~ 1 kg avg. increase in force

19. Slide 19: Inside Satellos

    © 2025 Satellos Bioscience Inside Satellos Our company and the team leading it forward

20. Slide 20: Overview of Ongoing and Planned Clinical Trials

    © 2025 Satellos Bioscience Overview of Ongoing and Planned Clinical Trials 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Ongoing Phase 1 Program (Underway: Australia) • Ph 1a Presented at • 72 HVs • SAD/MAD/FE MDA/2025 • Ph 1b Topline Data Reported • Up to 10 Adult DMD Patients • Safety + PK | 28 day at CureDuc

21. Slide 21: SAT-3247: Anticipated Program Milestones

    © 2025 Satellos Bioscience SAT-3247: Anticipated Program Milestones Ph1 a SAD/MAD study Ph1 b 28-day study Ph1 a + Potential Nasdaq Uplist top-line data (MDA) top-line data Ph1 b (CureDuchenne) Q4 2025 or Q1 2026 H1 2025 Ph1 b 11-month study (AUS) Date update: Data update: Data update: long-term mus

22. Slide 22: © 2025 Satellos Bioscience

    © 2025 Satellos Bioscience 22

Satellos Bioscience — Investor Presentation (June 2025) on 6ix